fashion -WSS

fashion

author：hotspot 2025-09-27 15:00:12 - browse：4986

The corporate offices of Massachusetts General Brigham hospitals in Assembly Square in Somerville. Lane Turner/Globe Staff

The severing of ties between two of Boston’s biggest health care giants has placed one of the nation’s largest health care systems in the position of figuring out how, exactly, to fill a new hole in its oncology services, at a time when cancer care is changing rapidly.

Earlier this month, Dana-Farber Cancer Institute surprised the medical community and even its partner, Brigham and Women’s Hospital, when it announced that it would end their nearly 30-year collaboration. The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians.

Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives. The two parties had been in discussions about extending their contract for months when the split was announced. “The decision was made by the Farber. It was announced. Now, we just have to plan forward,” she said. Klibanski shared her views on the split at a meeting with Boston Globe opinion editors on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： WuXi Biologics beefs up its lobbying operation

Wikipedia

WSS

WuXi Biologics execs register to lobby as Congress comes for the company

WuXi Biologics beefs up its lobbying operation

In diabetes hearing, Sanders takes on a new foe: food makers

HHS suspends federal funding for EcoHealth Alliance

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

entertainment

fashion

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

After sickle

Drug repurposing or repositioning? The language matters

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Sports medicine is finally prioritizing gender equality

Patients' immediate access to test results puts radiologists in a bind

Medicare proposal to cover medical devices draws a mixed reaction

Abbott's new stent may help patients with peripheral artery disease

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

focus

What causes an itch? Researchers may have solved the mystery

Boston hospital trains restaurant workers on naloxone for overdoses

Patients' immediate access to test results puts radiologists in a bind

What a koala virus tells us about the human genome

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Radiology is caught between AI's potential and concern for patients

Wikipedia

entertainment

entertainment

focus